Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIO752 in Early Alzheimer's Disease
NCT05469360Phase 1Active, not recruiting
- Sponsor
- Novartis
- Start
- Feb 2023
- Primary completion
- Jul 2026
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 4
01
Overview
Phase 1, randomised, double-blind trial of NIO752 in Alzheimer's disease (AD) (8 arms), sponsored by Novartis. Primary endpoint: Change in cerebrospinal total tau at Day 85. Started Feb 2023; status: active, not recruiting.
02
Drugs
NIO752
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05469360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05469360.